You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 20, 2024

CLINICAL TRIALS PROFILE FOR TUCATINIB

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for tucatinib

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01983501 ↗	A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer	Completed	Cascadian Therapeutics Inc.	Phase 1	2014-02-28	The purpose of this study is to determine the maximal tolerated dose (MTD) or recommended dose (RD) and to assess the safety and tolerability of tucatinib (ONT-380) combined with ado-trastuzumab emtansine (T-DM1) in patients with HER2+ breast cancer.
NCT01983501 ↗	A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer	Completed	Seagen Inc.	Phase 1	2014-02-28	The purpose of this study is to determine the maximal tolerated dose (MTD) or recommended dose (RD) and to assess the safety and tolerability of tucatinib (ONT-380) combined with ado-trastuzumab emtansine (T-DM1) in patients with HER2+ breast cancer.
NCT02025192 ↗	A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer	Completed	Cascadian Therapeutics Inc.	Phase 1	2013-12-31	The purpose of this study is to determine the maximal tolerated dose (MTD) or recommended phase 2 dose (RP2D) of tucatinib (ONT-380) and to assess the safety and tolerability of tucatinib (ONT-380) combined with capecitabine alone, trastuzumab alone and with both capecitabine and trastuzumab in patients with HER2+ metastatic breast cancer.
NCT02025192 ↗	A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer	Completed	Seagen Inc.	Phase 1	2013-12-31	The purpose of this study is to determine the maximal tolerated dose (MTD) or recommended phase 2 dose (RP2D) of tucatinib (ONT-380) and to assess the safety and tolerability of tucatinib (ONT-380) combined with capecitabine alone, trastuzumab alone and with both capecitabine and trastuzumab in patients with HER2+ metastatic breast cancer.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for tucatinib

Condition Name

Chart
Table

Condition Name for tucatinib
Intervention	Trials
Breast Cancer	9
HER2-positive Breast Cancer	5
Metastatic Breast Cancer	4
Colorectal Cancer	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for tucatinib
Intervention	Trials
Breast Neoplasms	28
Colorectal Neoplasms	7
Adenocarcinoma	7
Neoplasm Metastasis	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for tucatinib

Trials by Country

Map
Table

Trials by Country for tucatinib
Location	Trials
United States	310
Canada	22
Spain	17
Japan	11
Korea, Republic of	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for tucatinib
Location	Trials
Texas	19
California	17
Washington	14
Tennessee	13
New York	13
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for tucatinib

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for tucatinib
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	5
Phase 2/Phase 3	1
[disabled in preview]	21
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for tucatinib
Clinical Trial Phase	Trials
Not yet recruiting	18
Recruiting	16
Completed	8
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for tucatinib

Sponsor Name

Chart
Table

Sponsor Name for tucatinib
Sponsor	Trials
Seagen Inc.	30
Seattle Genetics, Inc.	13
Cascadian Therapeutics Inc.	5
[disabled in preview]	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for tucatinib
Sponsor	Trials
Industry	68
Other	33
NIH	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.